SPOTLIGHT REVIEW ARTICLE
ARTICLES IN THREE SENTENCES
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia
The persistence of measurable residual disease (MRD) after treatment has a well-established prognostic role in acute myeloid leukemia (AML). However, MRD assessment has yet to be standardized or routinely incorporated into clinical trials and discrepancies have been observed between different techniques for MRD assessment. Dillon and colleagues compared multiparametric flow cytometry versus next-generation sequencing-based AML MRD test in patients enrolled in a SWOG clinical trial, and showed that the molecular assay outperformed flow cytometry in identifying patients at high risk of adverse clinical outcomes and predicting their clinical response to treatment.
Efficacy and feasibility of pharmacoscopy-guided treatment for acute myeloid leukemia patients who have exhausted all registered therapeutic options
Improving the prognosis of patients with acute myeloiod leukemia (AML) who that have exhausted all registered therapy options remains an unsolved issue. The study of Schmid and colleagues aimed to establish whether pharmacoscopy - an image-based ex vivo functional drug testing platform - can be employed for therapy selection in AML patients lacking standard treatment and whether it can have an impact on outcome. They concluded that pharmacoscopy can rapidly provide valuable decision-making cues for therapy selection in late-stage AML patients, helping in the choice between established therapies and in the design of novel treatment plans.
Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis
The phase III IKEMA study compared Isatuximab (Isa), an anti-CD38 monoclonal antibody, in combination with carfilzomib (K) and dexamethasone (d) (Isa-Kd) versus Kd in patients with relapsed multiple myeloma (MM). Facon and colleagues present results of a subgroup analysis of the trial examining the efficacy and the safety of Isa-Kd versus Kd in patients who experienced early versus late relapse. Results support the addition of Isa to Kd as standard-of-care therapy for relapsed and/or refractory MM regardless of relapse timing.
Waldenström macroglobulinemia (WM) is a rare B-cellmalignancy characterized as an immunoglobulin M-secreting lymphoplasmacytic lymphoma. Xiong and colleagues studied the clinical and biological features, treatment response and outcome of oligosecretory WM, defined as WM with an initial amount of IgM lower than or equal to twice the upper limit of normal value. This study, from the Chinese Registration Network for WM, is the first analyzing the characteristics and survival of a large cohort of WM patients with very low IgM levels.
TAKE ADVANTAGE FROM HAEMATOLOGICA